BACKGROUND AND PURPOSE: In this study, the pharmacological activity of 33 compounds of furopyrimidine and thienopyrimidine as vascular endothelial growth factor receptor 2 (VEGFR-2) inhibitors to inhibit cancer was investigated. The most important angiogenesis inducer is VEGF endothelial growth factor, which exerts its activity by binding to two tyrosine kinase receptors called VEGFR-1 and VEGFR-2. Due to the critical role of VEGF in the pathological angiogenesis of this molecule, it is a valuable therapeutic target for anti-angiogenesis therapies. EXPERIMENTAL APPROACH: After calculating descriptors using SPSS software and stepwise selection method, 5 descriptors were used for modeling in multiple linear regression (MLR) and artificial neural network (ANN). The calibration series and the test series in this study included 26 and 7 combinations, respectively. FINDINGS/RESULTS: The performance evaluation of models was determined by the R(2), RMSE, and Q(2) statistic parameters. The R(2) values of MLR and ANN models were 0.889 and 0.998, respectively. Also, the value of RMSE in the ANN model was lower and its Q(2) value was higher than the MLR model. CONCLUSION AND IMPLICATIONS: The results were evaluated by different statistical methods and it was concluded that the nonlinear neural network method is powerful to predict the pharmacological activity of similar compounds, and because of the complex and nonlinear relationships, the MLR was not capable of establishing a good model with high predictive power.
QSAR analysis of pyrimidine derivatives as VEGFR-2 receptor inhibitors to inhibit cancer using multiple linear regression and artificial neural network.
阅读:6
作者:Masoomi Sefiddashti Fariba, Asadpour Saeid, Haddadi Hedayat, Ghanavati Nasab Shima
| 期刊: | Research in Pharmaceutical Sciences | 影响因子: | 2.100 |
| 时间: | 2021 | 起止号: | 2021 Oct 15; 16(6):596-611 |
| doi: | 10.4103/1735-5362.327506 | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
